

APPLYING NARROW BAND IMAGING[®] IN COMPLEMENT WITH WHITE-LIGHT IMAGING CYSTOSCOPY IN THE DETECTION OF UROTHELIAL CARCINOMA OF THE BLADDER

Guangfu Chen, M.D., Baojun Wang, M.D., Hongzhao Li, M.D., Xin Ma, M.D., Taoping Shi, M.D., Xu Zhang, M.D. Department of Urology, China PLA General Hospital, Beijing, China

OBJECTIVE

To investigate the value of narrow-band imaging (NBI®) flexible cystoscopy in the detection of urothelial carcinoma (UC) of the bladder.

EQUIPMENT USED



CYF-V2/VA2

Narrow band imaging view of carcinoma *in situ* (CIS) of urothelial carcinoma. White light imaging view of CIS (Left). Enhanced visualization of CIS with narrow band imaging (Right).

RESULTS

WLI and NBI confirmed UC in 143 patients; a total of 285 tumors were detected. The patient-level detection rates for NBI and WLI were 97.9% (140/143) and 88.8% (127/143), respectively (P = 0.002). The patient-level false-positive detection rates for NBI and WLI were 21.8% (39/179) and 29.1% (52/179), respectively (P = 0.12). NBI detected a total of 59 additional tumors (17.2%; 34pTa, 17pT1, 3pT2, and 5pTis) in 44 of 143 patients (30.8%). NBI found 1 additional tumor in 34 cases, 2 additional tumors in 6 cases, 3 additional tumors in 3 cases, and 4 additional tumors in 1 case. The mean \pm SD (range) number of identified UCs per patient was 1.97 \pm 0.67 (1-5) for NBI and 1.78 \pm 0.53 (1-4) for WLI (P = 0.01). The tumor-level detection rates for NBI and WLI were 96.8% and 79.3%, respectively (P < 0.001).

CONCLUSIONS

Compared with WLI, NBI improves UC detection. It has a higher rate of detection and a comparative rate of false-positive detection. NBI is simple and requires no dyeing. It can be conveniently applied to complement WLI.

Note: This summary is for informational purposes only. Publication abstract and access to full article can be found at: http://www.ncbi.nlm.nih.gov/pubmed/22079940 Ref: doi: 10.1016/j.urolonc.2011.02.009

© 2015 Olympus America, Inc. All rights reserved. Printed in USA. TM & Trademark or Registered Trademark of Olympus or its affiliated entities in the U.S. and/or other countries of the world. Subject to change without notice. OAIUR00215WP15116

